Parkinson Disease and Dementia

@article{GarcaPtacek2016ParkinsonDA,
  title={Parkinson Disease and Dementia},
  author={S. Garc{\'i}a-Ptacek and M. Kramberger},
  journal={Journal of Geriatric Psychiatry and Neurology},
  year={2016},
  volume={29},
  pages={261 - 270}
}
Dementia is a frequent complication of Parkinson disease (PD) with a yearly incidence of around 10% of patients with PD. Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid. The clinical phenotype in PDD extends beyond the dysexecutive syndrome that is often present in early PD and encompasses deficits in recognition memory, attention, and visual perception. Sleep disturbances… Expand
Parkinson's Disease: Cognitive Impairment.
TLDR
Since cognitive dysfunction is underdetected and undertreated in clinical practice, holistic psychiatric care of PD patients warrants appreciation of the clinical presentation, biopsychosocial features, and treatment of cognitive impairment. Expand
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
TLDR
A critical overview of dementia syndromes that overlap in many clinical features, genetics, neuropathology, and management is provided, suggesting that they share important common underlying molecular pathogenesis with Alzheimer’s disease and other proteinopathies. Expand
Lewy Body Dementias: A Coin with Two Sides?
TLDR
An overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD is provided, with a special focus on α-synuclein markers. Expand
Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia
TLDR
Cerebral amyloid angiopathy (CAA), often seen in AD, is increasingly recognized for its association with dementia. Expand
Available and future treatments for atypical parkinsonism. A systematic review
  • D. Moretti
  • Medicine
  • CNS neuroscience & therapeutics
  • 2019
TLDR
The present work overviews the most influential research literature collected on MEDLINE, ISI Web of Science, Cochrane Library, and Scopus for available treatment in atypical parkinsonisms without time restriction. Expand
Review: Clinical, neuropathological and genetic features of Lewy body dementias
TLDR
The aim of this article is to review the main clinical, neuropathological and genetic aspects of dementia with Lewy bodies and Parkinson's disease dementia, particularly relevant as future management for these two conditions may differ. Expand
Dementia-Related Functional Disability in Moderate to Advanced Parkinson’s Disease: Assessment Using the World Health Organization Disability Assessment Schedule 2.0
TLDR
It is suggested that deteriorating social relationships were a dementia-related disability in all PwP at the moderate and advanced disease stages and could indicate cognitive impairment in people with moderate or advanced PD. Expand
Assessment of individual cognitive changes after deep brain stimulation surgery in Parkinson’s disease using the Neuropsychological Test Battery Vienna short version
TLDR
Roughly 10% of DBS patients showed cognitive decline mainly affecting the domains attention and executive functioning (phonemic fluency), and further research is needed to identify the mechanisms that lead to improvement or deterioration of cognitive functions in individual cases. Expand
Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson’s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis
TLDR
A meta-analysis showed that CSF Aβ42 level in PDCI cohort was lower than that in PDNC cohort, and amyloid pathology and tauopathy may participate in the development of PDD, which is similar to AD. Expand
Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson’s disease
TLDR
DIP can serve as a strong proxy for IPD incidence and might not be from the causal toxicity of antidopaminergic effects but from a trigger by the causative drugs on the DIP patients who already had subclinical IPD pathology. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 145 REFERENCES
The Epidemiology of Dementia Associated with Parkinson's Disease
TLDR
The purpose of this review is to present recent findings on clinical aspects of dementia in PD and to elucidate underlying clinical and neurobiological risk factors. Expand
Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
  • D. Aarsland
  • Psychology, Medicine
  • Parkinsonism & related disorders
  • 2016
TLDR
There is good evidence for cholinesterase inhibitors in both DLB and PD with dementia, and some indications that memantine is helpful, and disease-modifying agents that delay the rate of cognitive decline in PD and DLB are urgently needed. Expand
Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease
The non-motor symptoms of Parkinson’s disease (PD) have been attracting increasing attention due to their ubiquitous nature and their often devastating effects on the quality of life. BehavioralExpand
Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?
TLDR
Given the predominance of Parkinsonism in PDD, neuronal loss in the substantia nigra is more severe inPDD than DLB, and further clinicopathologic studies are needed to define other pathologic differences between DLB and PDD and to explore the role of neuritic, basal forebrain and striatal pathology in these clinical syndromes. Expand
[Genetic factors associated with dementia in Parkinson's disease (PD)].
TLDR
In a review of the literature, it is found that mutations in the alpha-synuclein gene are the most responsible for developing dementia, either from PARK1 or 4 mutations. Expand
The spectrum of cognitive impairment in Lewy body diseases
TLDR
The spectrum and evolution of cognitive impairment in Lewy body disorders is examined and the conundrum of whether Parkinson's disease dementia and dementia with Lewy bodies represent the same or different entities remains unresolved. Expand
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
TLDR
Remediation and management prospects for cognitive deficits in patients with Parkinson's disease are based on neuropharmacological and cognitive rehabilitation approaches, supplemented by advances in neuroimaging and genetic research. Expand
Cognitive impairment and dementia in Parkinson's disease
TLDR
Major differences in the overall rate of cognitive decline among PD patients support the co-existence of at least two patterns of involution, differentiating a relatively slow decline of fronto-striatal deficits from a more rapid decline of posterior-cortical deficits. Expand
Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study
TLDR
It was concluded that poor performance on a test sensitive to executive dysfunction predicted later development of dementia in PD patients, and this finding may have important clinical implications as a marker of subsequentDevelopment of dementia. Expand
The neurobiological basis of cognitive impairment in Parkinson's disease
TLDR
Critical assessment of animal models shows that chronic low‐dose MPTP treatment in primates recapitulates PD‐MCI over time, enhancing the current biological concept of PD‐ MCI as having enhanced dopamine deficiency in frontostriatal pathways as well as involvement of other neurotransmitter systems. Expand
...
1
2
3
4
5
...